Synthesis of trans-Fused 3,6-Anhydro Hexofuranose Frameworks via Catalytic Hydrogenolysis Triggered Debenzylative Intramolecular Acetalation.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-01-19 DOI:10.1002/cmdc.202400907

Yu Li, Zhi-Mei Wang, Wen-Xiang Tao, Jian-Chen Yang, Genzoh Tanabe, Osamu Muraoka, Wei Li, Wei-Jia Xie

引用次数: 0

Abstract

Presented herein is the chemical construction of unprecedented 3,4-trans-3,6-anhydro hexofuranose frameworks. The disfavored 3,6-anhydro hexofuranosides were effectively established by Pd-catalyzed debenzylative intramolecular acetalation for the first time. The critical roles of benzyl protection and Pd as catalyst were demonstrated. Various 3,4-trans-3,6-anhydro sugars including sauropunol E was first obtained in satisfactory yields. Pharmaceutical investigation of the sauropunol E and its analogues revealed their potential application as anti-inflammatory agents.

查看原文本刊更多论文

催化氢解引发脱苯缩分子内缩合反应合成反融合3,6-无水己糖框架。

本文介绍了前所未有的3,4-反式3,6-无水己糖框架的化学结构。首次通过pd催化脱苯缩化反应有效地合成了不受欢迎的3,6-无羟基己糖苷类化合物。证明了苯保护和钯作为催化剂的重要作用。各种3,4-反式3,6-无水糖，包括索罗普醇E，首次得到了令人满意的产率。索罗普诺尔E及其类似物的药理研究揭示了其作为抗炎药的潜在应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.